Home » News » FTSE 250 » PureTech Health Affiliate Vedanta Biosciences Awarded $5.8 Million CARB-X Grant
PureTech Health PLC

PureTech Health Affiliate Vedanta Biosciences Awarded $5.8 Million CARB-X Grant

PureTech Health plc (LON: PRTC) a clinical stage biotechnology company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, has today noted that its affiliate, Vedanta Biosciences, has been awarded a $5.8 million grant for its VE707 programme targeting multi-drug resistant infections. The grant was awarded by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating early development in antibacterial R&D to address the rising global threat of drug-resistant bacteria. Vedanta Biosciences is eligible for $3.5 million in further funding upon completion of specific milestones.

Bharatt Chowrira, JD, PhD, president and chief of business and strategy at PureTech Health said:

“Increasingly the human microbiome is being colonised by dangerous bacteria and other microorganisms that have developed resistance to antimicrobial drugs, mainly through poor global stewardship of antibiotics. This grant from CARB-X recognises Vedanta’s unique platform and advanced understanding of the human gut microbiome for developing live biotherapeutic products with the potential to modulate the intestinal microbiome to address a range of significant human diseases and health issues, including drug-resistant pathogens.”

Join us on our new LinkedIn page

Follow us on LinkedIn